News Archive

DATE AND TIME: Tue, September 19, 20177:30 AM – 10:00 AM EDT

LOCATION: American Visionary Art Museum800 Key Highway JRVC 3rd Floor Baltimore, MD 21230

Already dubbed a ‘tech hub’, the Baltimore-Washington region has built a solid foundation in cyber activities as they pertain to government agencies and defense contracting. Now a transformation is underway to build up the commercial side of cyber. And that’s precisely what this panel will reinforce.

Cambridge headquartered AstraZeneca and its global biologics R & D arm MedImmune, plan to develop new therapies for respiratory disease through a five-year collaboration with Munich-based Ethris GmbH.

The Cambridge UK duo will pay Ethris €25 million upfront, plus research funding; Ethris is also eligible for future R & D milestones, including sales-related royalties on commercialisation.

Gaithersburg-based immunotherapy company Altimmune Inc. announced Tuesday it plans to expand into a new headquarters, but it’s not going far.

Altimmune (NASDAQ: ALT) officials said they plan to relocate existing employees — as well as new employees acquired as a result of its acquisition of Annapolis biodefense company PharmAthene Inc. — to a 14,000-square-foot space at 910 Clopper Road. The company is currently based at 19 Firstfield Road, less than a mile away.

Intralytix, Inc. announced that it received $17.5 million in new equity funding from Lesaffre, a French family group. This investment marks the beginning of a close collaboration between both companies to develop and commercialize bacteriophage-based products, for various benefits in human health and in other areas of mutual interest.

As a global key player in yeasts and fermentation, Lesaffre designs, manufactures and markets innovative solutions for Baking, Food taste & pleasure, Health care and Biotechnology. This new investment is perfectly in line with Lesaffre’s ongoing expansion strategy in nutrition and health. In 2015, Lesaffre had already announced the investment in Gnosis, an Italian company specialized in ingredients for the pharmaceutical, nutraceutical, cosmetic and veterinary industries.

Deadline Extended to August 24, 2017! Submit your proposal today

There’s still time to submit your proposal for the “Make Your Medical Device Pitch for Kids!” competition. Deadline extended to Thursday, August 24, 2017 at midnight PDT.

Up to six prizes totaling $250,000 will be awarded to the winning presentations at the nation’s leading pediatric innovation symposium on Sunday, September 24, 2017. Are you registered for the Symposium?

Join us for the 5th Annual Pediatric Device Innovation Symposium in San Jose, CA – one day before The MedTech Conference powered by AdvaMed.

It’s a results-driven day that brings together medical device innovators, investors, researchers, clinicians, and policy makers to stimulate pediatric device innovation and bring solutions to market faster for the benefit of children everywhere.

Innovation is a principal driver of U.S. economic growth. In 2016, the U.S. spent an estimated $514 billion on research and development — more than any other country in the world — helping the nation rank No. 4 on the Global Innovation Index. According to the results of the ranking, knowledge and technology outputs are America’s particular strengths.

But certain states are due more credit than others for America’s dominance in the tech era. These states continue to foster innovation through investments in education, research and business creation, especially in highly specialized industries.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced, following a four-day bench trial, that the United States District Court for the District of New Jersey ruled that TWi Pharmaceuticals, Inc. and its subsidiary infringed U.S. Patent Nos. 7,722,898, 7,910,131, and 8,821,930 by submitting to the FDA an Abbreviated New Drug Application (ANDA) seeking permission to market a generic version of Oxtellar XR® before the expiration of Supernus’ patents.  The District Court ruling also confirmed the validity of U.S. Patent Nos. 7,722,898, 7,910,131, and 8,821,930.

The National Institute of Standards and Technology on Wednesday published new guidance on how to strengthen passwords. Why now? Research shows that the de facto standard practice of requiring users to include a mix of uppercase and lowercase letters, numbers and at least one symbol, is more trouble than it’s worth.

“Analyses of breached password databases reveal that the benefit of such rules is not nearly as significant as initially thought,” NIST explained. “The impact on usability and memorability is severe.”

Maryland gained 800 jobs in July and unemployment fell for the third consecutive month.

The private sector added 11,500 positions while government positions decreased by 10,700, according to preliminary data released Friday by the U.S. Department of Labor. Maryland’s unemployment rate dropped to 4 percent in July from 4.1 percent.